A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.
Laderach DJ, et al. Among authors: chauchereau a.
Cancer Res. 2013 Jan 1;73(1):86-96. doi: 10.1158/0008-5472.CAN-12-1260. Epub 2012 Oct 29.
Cancer Res. 2013.
PMID: 23108139